ReviewJournal of applied genetics2026
Molecular interplay of lncRNAs, miRNAs, and mRNAs axes in triple-negative breast cancer: implications for metastatic progression.
Review in Journal of applied genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) constitutes 15-17% of all breast cancer cases. The absence of molecular targets restricts targeted therapy options for TNBC. Despite the availability of conventional chemotherapy, high recurrence rates and metastasis remain the primary challenges in current disease management. Nearly 46% of TNBC cases are metastasized to distant organs, which decreases the overall survival of TNBC patients. Therefore, identifying disease-specific markers, their mechanisms in metastasis, and their therapeutic potential could aid in developing better treatment options for patients. Long non-coding RNAs (lncRNAs), a subset of non-coding RNAs (> 200 nucleotides), exhibit significant function in gene expression regulation and tumorigenesis. LncRNAs play a significant role in TNBC metastasis through diverse mechanisms. LncRNAs such as H19, MALAT1, and others contribute to TNBC chemotherapy resistance, invasion, migration, relapse, and immune suppression. Furthermore, the molecular interactions among lncRNAs, miRNAs, and mRNAs collectively drive key hallmarks of metastatic progression, specifically in TNBC. To provide a comprehensive understanding of these mechanisms, this review highlights the biogenesis, classification, and physiological functions of lncRNAs, along with an overview of the metastatic cascade. Specifically, it emphasizes the regulatory axes of lncRNAs with miRNAs and mRNAs in driving metastatic progression, and explores their emerging role as promising biomarkers for diagnosis and targeted therapy. Expanding the understanding of lncRNA-mediated regulatory interactions could pave the way for the identification of novel biomarkers and the development of more effective therapeutic strategies to enhance TNBC diagnosis, prognosis, and treatment outcomes.
Indexed as
Identifiers
42020663What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.